Abbott (ABT) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY25 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Abbott Labs (ABT) PT Lowered to $155 at Citi
July 18, 2025 10:03 AM EDTCiti analyst Joanna Wuensch lowered the price target on Abbott Labs (NYSE: ABT) to $155.00 (from $157.00) while maintaining a Buy rating.
The analyst comments "This was a somewhat precarious setup for ABT heading into the quarter, priced for a beat-and-raise, which did not... More
Goldman Sachs Reiterates Buy Rating on Abbott Labs (ABT)
July 17, 2025 9:45 AM EDTGoldman Sachs analyst David Roman reiterated a Buy rating and $153.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "This morning, Abbott reported 2Q25 results and updated 2025 guidance. The headline that we expect to gain most attention is the reduction to the... More
